PRME
Prime Medicine, Inc.Marquee-fund ownership over time
This quarter's activity
New positions opened
None.
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Citadel Advisors re-entered | Q3 2024(8Q snapshot) | 7Q | $4.11 | $2.81 | -32% |
| Two Sigma Investments | Q3 2024(8Q snapshot) | 7Q | $4.11 | $2.81 | -32% |
| D.E. Shaw re-entered | Q3 2024(8Q snapshot) | 7Q | $4.11 | $2.81 | -32% |
| AQR Capital Management re-entered | Q3 2024(8Q snapshot) | 7Q | $4.11 | $2.81 | -32% |
| Renaissance Technologies re-entered | Q4 2024(8Q snapshot) | 6Q | $3.96 | $2.81 | -29% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Millennium Management | Q3 2024 | Q2 2026 | → $2.93 | -29% |
| Point72 Asset Management 2× in & out | Q1 2026 | Q2 2026 | → $2.93 | -11% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Prime Medicine, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Jun 8, 2026 — the most recent Form 4 on file — not from today.
- Form 40001628280-26-041579Jun 8, 2026
- Form 40001628280-26-041575Jun 8, 2026
- Form 40001628280-26-041572Jun 8, 2026
- Form 40001628280-26-041569Jun 8, 2026
- Form 40001628280-26-041566Jun 8, 2026
- Form 40001628280-26-041560Jun 8, 2026
- Form 40001628280-26-041553Jun 8, 2026
- Form 40001470831-26-000388Apr 17, 2026
- Form 40001628280-26-012893Feb 27, 2026
- Form 40001628280-26-011208Feb 24, 2026
- Form 40001628280-26-011181Feb 24, 2026
- Form 40001894562-25-000051Aug 5, 2025
- Form 40001894562-25-000050Aug 5, 2025
- Form 40001894562-25-000049Aug 5, 2025
- Form 40001894562-25-000048Aug 5, 2025
Fundamentals
XBRL · Prime Medicine, Inc.Annual figures sourced directly from Prime Medicine, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Prime Medicine, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventJun 8, 2026
- 10-QQuarterly reportMay 7, 2026
- 8-KMaterial eventMay 7, 2026
- DEF 14AProxy statementApr 23, 2026
- 8-KMaterial eventApr 16, 2026
- 10-KAnnual reportMar 3, 2026
- 8-KMaterial eventMar 3, 2026
- 8-KMaterial eventJan 12, 2026
- 10-QQuarterly reportNov 7, 2025
- 8-KMaterial eventNov 7, 2025
- 8-KMaterial eventSep 8, 2025
- 10-QQuarterly reportAug 7, 2025
- 8-KMaterial eventAug 7, 2025
- 8-KMaterial eventAug 5, 2025
- 8-KMaterial eventJul 31, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Point72 Asset Management | Q1 2026 | Q2 2026 | $3.31 | $2.93 | -11% |
| D.E. Shaw | Q4 2025 | open | $3.37 | $2.81 | -17% |
| Citadel Advisors | Q3 2025 | open | $3.64 | $2.81 | -23% |
| Renaissance Technologies | Q2 2025 | open | $1.21 | $2.81 | +132% |
| AQR Capital Management | Q1 2025 | open | $2.84 | $2.81 | -1% |
| Point72 Asset Management | Q1 2025 | Q2 2025 | $2.84 | $1.26 | -56% |
| Renaissance Technologies | Q4 2024 | Q1 2025 | $3.96 | $2.60 | -34% |
| Citadel Advisors | Q3 2024 | Q1 2025 | $4.11 | $2.84 | -31% |
| Two Sigma Investments | Q3 2024 | open | $4.11 | $2.81 | -32% |
| D.E. Shaw | Q3 2024 | Q1 2025 | $4.11 | $2.84 | -31% |
| AQR Capital Management | Q3 2024 | Q4 2024 | $4.11 | $3.60 | -13% |
| Millennium Management | Q3 2024 | Q2 2026 | $4.11 | $2.93 | -29% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.